Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombasthenia Anti-αIIbβ3 Antibodies Study
NCT04595617Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2021
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Single-arm trial, sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoints: Characterization of change of an anti-αIIbβ3 immunization at 18 months and Number of patients with positive anti-αIIbβ3 antibodies in relation to risk factors at 18 months. Started Jan 2021; status: completed.
Beyond the preview
Go deeper on NCT04595617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595617.